Foghorn Therapeutics (FHTX) EBITDA (2019 - 2026)

Foghorn Therapeutics' EBITDA history runs 8 years deep, the most recent figure standing at -$21.6 million for Q1 2026.

• In Q1 2026, EBITDA rose 5.85% year-over-year to -$21.6 million; the TTM figure through Mar 2026 stood at -$85.0 million (up 12.68% YoY), while the FY2025 annual figure was -$86.4 million, up 15.87% from the prior year.
• EBITDA for Q1 2026 stood at -$21.6 million, up from -$23.9 million in the prior quarter.
• The five-year high for EBITDA was -$17.1 million in Q3 2023, with the low at -$33.3 million in Q1 2023.
• The 5-year median for EBITDA is -$25.5 million (2023), against an average of -$25.6 million.
• The sharpest annual moves came in 2023 and 2024: EBITDA jumped 39.56% in 2023, then plunged 39.64% in 2024.
• Foghorn Therapeutics' EBITDA stood at -$31.9 million in 2022, then increased by 20.16% to -$25.5 million in 2023, then increased by 5.71% to -$24.0 million in 2024, then climbed by 0.53% to -$23.9 million in 2025, then increased by 9.65% to -$21.6 million in 2026.
• Business Quant data shows FHTX's EBITDA at -$21.6 million in Q1 2026, -$23.9 million in Q4 2025, and -$18.5 million in Q3 2025.